Advertisement
MRNA vs NVDA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MRNA is a Hold and NVDA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
MRNA’s FA Score shows that 1 FA rating(s) are green whileNVDA’s FA Score has 3 green FA rating(s).
- MRNA’s FA Score: 1 green, 4 red.
- NVDA’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
MRNA’s TA Score shows that 4 TA indicator(s) are bullish while NVDA’s TA Score has 2 bullish TA indicator(s).
- MRNA’s TA Score: 4 bullish, 4 bearish.
- NVDA’s TA Score: 2 bullish, 4 bearish.
Price Growth
MRNA (@Biotechnology) experienced а -1.27% price change this week, while NVDA (@Semiconductors) price change was +1.55% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.91%. For the same industry, the average monthly price growth was +35.46%, and the average quarterly price growth was +17.29%.
The average weekly price growth across all stocks in the @Semiconductors industry was +2.87%. For the same industry, the average monthly price growth was +11.31%, and the average quarterly price growth was -5.16%.
Reported Earning Dates
MRNA is expected to report earnings on Jul 31, 2025.
NVDA is expected to report earnings on Aug 27, 2025.
Industries' Descriptions
@Biotechnology (+4.91% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Semiconductors (+2.87% weekly)The semiconductor industry manufacturers all chip-related products, including research and development. These chips are used in innumerable electronic devices, including computers, cell phones, smartphones, and GPSs. Intel Corporation, NVIDIA Corp., and Broadcomm are some of the prominent players in this industry. Semiconductor companies usually tend to do well during periods of healthy economic growth, thereby inducing further research and development in the industry – which in turn augurs well for productivity and growth in the economy. In the near future, demand for semiconductor products (and possibly innovation within the segment) should only expand further, with the proliferation of 5G, autonomous vehicles, IoT, and various AI-driven electronics set to herald a new, advanced chapter in the technology-driven world as we know it. With burgeoning prospects comes great competition. In 2015, SIA estimated that U.S. semiconductor industry ranks as the second most competitive U.S. industry out of 2882 U.S. industries designated manufacturers by the U.S. Census Bureau.
| MRNA | NVDA | MRNA / NVDA | |
| Capitalization | 10B | 3.51T | 0% |
| EBITDA | -3.2B | 91B | -4% |
| Gain YTD | -38.264 | 7.375 | -519% |
| P/E Ratio | N/A | 46.51 | - |
| Revenue | 3.14B | 149B | 2% |
| Total Cash | 5.98B | 52.7B | 11% |
| Total Debt | 745M | 10.3B | 7% |
MRNA | NVDA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 61 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 12 | |
SMR RATING 1..100 | 96 | 12 | |
PRICE GROWTH RATING 1..100 | 65 | 18 | |
P/E GROWTH RATING 1..100 | 2 | 86 | |
SEASONALITY SCORE 1..100 | 50 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MRNA's Valuation (62) in the Biotechnology industry is somewhat better than the same rating for NVDA (98) in the Semiconductors industry. This means that MRNA’s stock grew somewhat faster than NVDA’s over the last 12 months.
NVDA's Profit vs Risk Rating (12) in the Semiconductors industry is significantly better than the same rating for MRNA (100) in the Biotechnology industry. This means that NVDA’s stock grew significantly faster than MRNA’s over the last 12 months.
NVDA's SMR Rating (12) in the Semiconductors industry is significantly better than the same rating for MRNA (96) in the Biotechnology industry. This means that NVDA’s stock grew significantly faster than MRNA’s over the last 12 months.
NVDA's Price Growth Rating (18) in the Semiconductors industry is somewhat better than the same rating for MRNA (65) in the Biotechnology industry. This means that NVDA’s stock grew somewhat faster than MRNA’s over the last 12 months.
MRNA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for NVDA (86) in the Semiconductors industry. This means that MRNA’s stock grew significantly faster than NVDA’s over the last 12 months.
| MRNA | NVDA | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 71% |
| Stochastic ODDS (%) | 2 days ago 74% | 2 days ago 67% |
| Momentum ODDS (%) | 2 days ago 86% | N/A |
| MACD ODDS (%) | 2 days ago 77% | 2 days ago 63% |
| TrendWeek ODDS (%) | 2 days ago 85% | 2 days ago 82% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 80% |
| Advances ODDS (%) | 16 days ago 77% | 15 days ago 83% |
| Declines ODDS (%) | 7 days ago 85% | N/A |
| BollingerBands ODDS (%) | 2 days ago 76% | 2 days ago 70% |
| Aroon ODDS (%) | N/A | 2 days ago 88% |
Advertisement